Apatinib preferentially inhibits PC9 gefitinib-resistant cancer cells by inducing cell cycle arrest and inhibiting VEGFR signaling pathway
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1475-2867
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Apatinib preferentially inhibits PC9 gefitinib-resistant cancer cells by inducing cell cycle arrest and inhibiting VEGFR signaling pathway ; volume:19 ; number:1 ; day:2 ; month:5 ; year:2019 ; pages:1-15 ; date:12.2019
Cancer cell international ; 19, Heft 1 (2.5.2019), 1-15, 12.2019
- Klassifikation
-
Medizin, Gesundheit
- Urheber
-
Song, Yong-An
Ma, Ting
Zhang, Xue-Yan
Cheng, Xiang-Song
Olajuyin, Ayobami-Matthew
Sun, Zhi-Fu
Zhang, Xiao-Ju
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s12935-019-0836-8
- URN
-
urn:nbn:de:101:1-2019052122184702748397
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:50 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Song, Yong-An
- Ma, Ting
- Zhang, Xue-Yan
- Cheng, Xiang-Song
- Olajuyin, Ayobami-Matthew
- Sun, Zhi-Fu
- Zhang, Xiao-Ju
- SpringerLink (Online service)
Ähnliche Objekte (12)
Src Kinase becomes preferentially associated with the VEGFR, KDR/Flk-1, following VEGF stimulation of vascular endothelial cells
Osteoclast-expanded super-charged NK-cells preferentially select and expand CD8+ T cells
The ACTIVE study protocol: apatinib or placebo plus gefitinib as first-line treatment for patients with EGFR-mutant advanced non-small cell lung cancer (CTONG1706)
Clinical benefit of readministration of gefitinib for initial gefitinib-responders with non-small cell lung cancer
Synergistic effect of gefitinib and rofecoxib in mesothelioma cells
Subconjunctival aflibercept inhibits corneal angiogenesis and VEGFR-3+CD11b+ cells
RCAN1.4 regulates VEGFR-2 internalisation, cell polarity and migration in human microvascular endothelial cells
Gefitinib radiosensitizes non-small cell lung cancer cells through inhibition of ataxia telangiectasia mutated
Elevated expression of VEGFR-3 in lymphatic endothelial cells from lymphangiomas
Apatinib monotherapy for early non-small cell lung cancer: a case report
Enhanced interaction between natural killer cells and lung cancer cells: involvement in gefitinib-mediated immunoregulation
All-trans retinoic acid reduces cancer stem cell-like cell-mediated resistance to gefitinib in NSCLC adenocarcinoma cells
Src Kinase becomes preferentially associated with the VEGFR, KDR/Flk-1, following VEGF stimulation of vascular endothelial cells
Osteoclast-expanded super-charged NK-cells preferentially select and expand CD8+ T cells
The ACTIVE study protocol: apatinib or placebo plus gefitinib as first-line treatment for patients with EGFR-mutant advanced non-small cell lung cancer (CTONG1706)
Clinical benefit of readministration of gefitinib for initial gefitinib-responders with non-small cell lung cancer
Synergistic effect of gefitinib and rofecoxib in mesothelioma cells
Subconjunctival aflibercept inhibits corneal angiogenesis and VEGFR-3+CD11b+ cells
RCAN1.4 regulates VEGFR-2 internalisation, cell polarity and migration in human microvascular endothelial cells
Gefitinib radiosensitizes non-small cell lung cancer cells through inhibition of ataxia telangiectasia mutated
Elevated expression of VEGFR-3 in lymphatic endothelial cells from lymphangiomas
Apatinib monotherapy for early non-small cell lung cancer: a case report
Enhanced interaction between natural killer cells and lung cancer cells: involvement in gefitinib-mediated immunoregulation
All-trans retinoic acid reduces cancer stem cell-like cell-mediated resistance to gefitinib in NSCLC adenocarcinoma cells
Src Kinase becomes preferentially associated with the VEGFR, KDR/Flk-1, following VEGF stimulation of vascular endothelial cells
Osteoclast-expanded super-charged NK-cells preferentially select and expand CD8+ T cells
The ACTIVE study protocol: apatinib or placebo plus gefitinib as first-line treatment for patients with EGFR-mutant advanced non-small cell lung cancer (CTONG1706)
Clinical benefit of readministration of gefitinib for initial gefitinib-responders with non-small cell lung cancer
Synergistic effect of gefitinib and rofecoxib in mesothelioma cells
Subconjunctival aflibercept inhibits corneal angiogenesis and VEGFR-3+CD11b+ cells
RCAN1.4 regulates VEGFR-2 internalisation, cell polarity and migration in human microvascular endothelial cells
Gefitinib radiosensitizes non-small cell lung cancer cells through inhibition of ataxia telangiectasia mutated
Elevated expression of VEGFR-3 in lymphatic endothelial cells from lymphangiomas
Apatinib monotherapy for early non-small cell lung cancer: a case report
Enhanced interaction between natural killer cells and lung cancer cells: involvement in gefitinib-mediated immunoregulation